HAB Performance Measures Companion Guide -
Elements of HAB Core Clinical Performance Measures

< Previous | Home | Next >

HRSA's Office of Performance Review (OPR) conducts site visits (performance reviews) to programs that receive funding from HRSA. As part of the site visit, a few performance measures are selected and used during the process. Some of the OPR measures are similar or the same as HAB's clinical performance measures. In those instances, "OPR-Related Measure: Yes" is referenced in the upper right hand corner of the table.  "OPR-Related Measure: No" indicates there is not a corresponding measure.  Additional information about the OPR site visit process and list of performance measures can be located at: http://www.hrsa.gov/performancereview/.

For each performance measure an eligible population must be determined. Depending on the element of care being measured, certain patients should be excluded from the denominator in order to gather accurate data. For instance, in the HAART measure, patients seen for the first time in the last three (3) months of the measurement year will be excluded because a provider generally needs at least two (2) visits to evaluate the patient prior to prescribing HAART. Once the exclusions are applied and the population defined, the data elements are used to collect information on the performance measure.

First and foremost it is important to understand that the data reflect similar, but not the exact performance measure. They may vary in purpose or definition. The similarities do, however, provide an opportunity to compare performance from your organization to the performance of other Ryan White programs. For instance, an IHI goal for cervical cancer screening was set for 90% and data for the National HIVQUAL Project show the median at 73.7%, with sites performing in the top 10% reaching 100%. If your program is struggling with a completion rate of 34%, using the comparative data highlights potential disparity between your site and other programs. This type of information can then be used to set realistic goals and priorities for quality improvement projects.

During the comment period many respondents requested specific outcome measures identified as a way to move their quality management programs along. By including the section "Outcome Measures for Consideration", HAB is providing direction on potential areas of focus.

For the purposes of these measures, an HIV care setting is one which receives Ryan White HIV/AIDS Treatment Modernization Act of 2006 funding to provide HIV care. Each program receiving these funds is required to implement a quality management program to monitor the quality of care and address needs as appropriate.

For the purposes of these measures, a medical visit is considered any visit with a health care professional who is certified in their jurisdiction and has prescribing privileges.

Because lab tests do not have to coincide with a medical visit to a provider with prescribing privileges, a lab test can not be used as a surrogate marker for a medical visit.

No, a phone consultation can not be counted as a medical visit.

HAART stands for "highly active antiretroviral therapy" and refers to combination antiretroviral therapy that is of sufficient potency to achieve an undetectable viral load in most all cases. Guidelines on HAART can be found at http://www.aidsinfo.nih.gov/.

It is understood that patients, for many reasons, may choose not to fill or take a prescribed treatment and it is not expected that programs will have attained 100% compliance on the measures. However, it is important for programs to capture the actual percentage of clients that are on a prescribed treatment regimen and identify opportunities for improvement. Often times when programs begin to track and trend data, they find unexpected levels of performance and new opportunities for improvement.

For HIV care, CD4+ percentage is routinely used to monitor children age 12 years and younger. A separate set of clinical performance measures will be developed for the pediatric population.

Adherence assessment and counseling occur in the context of comprehensive medical care. Anyone on the care team can conduct the assessment or provide counseling as long as appropriate feedback is given to the provider so that treatment changes can be made as necessary. Sessions provided as part of the medical visit can be counted and do not require a separate visit. Assessment of adherence can include patient reports through the use of quantifiable scales, such as missing 9 out of 10 doses, or through qualitative Likert scales which rate a response based on a numeric scale, e.g. 1-5. Assessment can also be made through quantified reviews such as pill counts or pharmacy dispensing records.

Risk counseling includes the assessment of risk, provision of counseling and as necessary, referrals to appropriate resources. As with adherence assessment and counseling, risk counseling occur in the context of comprehensive medical care. Anyone on the care team can provide the counseling as long as appropriate feedback is given to the provider so that the treatment plan and approach can be modified as necessary. Sessions provided as part of the medical visit can be counted and do not require a separate visit.

The answer depends on the reason for the hysterectomy. If the hysterectomy was performed for non-dysplasia or non-malignant conditions, then a Pap screen does not need to be completed. In these instances, the client would be excluded from the denominator. If, however, the hysterectomy was performed because of dysplasia or cancer, Pap screens should be completed and the client should be included in the denominator.

If the glans penis was used to construct the cervix then Pap screens should be completed according to the same schedule recommended for all women.

There are different rules of coverage, depending on the situation of the patient.

• Lipid evaluation as a screening test: A patient entitled to Medicare Part B may receive coverage of screening blood tests for the early detection of cardiovascular disease in individuals without signs or symptoms of heart disease and stroke. This Medicare cardiovascular screening benefit includes coverage of the use of three screening blood tests, a total cholesterol, a HDL, cholesterol, and a triglycerides tests (performed after a 12-hour fasting period) ordered individually or together as a lipid panel (CPT code 80061). Frequency of coverage is limited to either each individual test or 1 lipid panel every 5 years. If any abnormal value is obtained in performing these screening tests, further testing may be covered under the diagnostic clinical laboratory benefit, if it is ordered by the patient's physician and the local Medicare contractor determines that it is medically necessary for the patient in accordance with the coverage policy on lipid testing as described in section 190.23 of the Medicare National Coverage Determinations (NCD) Manual.
• Lipid evaluation to assess for lipid perturbations caused by antiretroviral agents: If the patient is prescribed a medication that may cause lipid perturbations, such as occurs with some antiretroviral agents, the lipid test is not a true "screening" test, but a diagnostic test. In this setting, a lipid panel (CPT code 80061) may be covered by Medicare if the diagnostic code of 272.6 (Lipodystrophy) or V58.69 (Long term [current] use of other medicines) is applicable and used for that visit and the local Medicare contractor determines that such coverage is consistent with the coverage policy on lipid testing as described in section 190.23 of the Medicare NCD Manual.

The measure is designed to capture the percentage of clients who completed the vaccination series, which represents a 3-dose schedule. The denominator represents those clients who were seen in the measurement year and had no documentation of ever having vaccination or documented susceptibility to Hepatitis B. Comparing those who were eligible for the vaccination series (denominator) with those who received the series (numerator), the percentage can be calculated. Clients new to care in the measurement year may have begun the series, but may not have completed the entire course within the defined time period.

At the client level, it is important to determine if the client was eligible and had received Hepatitis B vaccination at one point during the client's life. When looking at data over time, the focal point shifts and concentrates on completion rates of the vaccination series for the clinic population as a whole. If the rates of completion are lower than desired, specific points of influence can be explored to have a positive impact and raise the rates. Potential points of influence (or areas for improvement) can be related to the process of notifying the provider of an impending vaccine, reminding clients of appointments to receive the vaccination or patient education about the need and importance of the vaccination. Any one of these areas could have a positive impact on the completion rates of vaccination series.

In certain persons, the only HBV serologic marker detected in serum is anti-HBc and may not be detectable by commercial serology [ 1 ]. Therefore, including or excluding patients with isolated anti-HBc depends on the rate of prevalence of Hepatitis B in the clinic population. Some experts recommend persons who are positive only for anti-HBc and who are from a low endemic area with no risk factors for HBV should be given the full series of Hepatitis B vaccine [ 2 ]. Re-evaluation is recommended if there is no response after vaccination. Additional information can be found at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5516a1.htm

[ 1 ] Centers for Disease Control and Prevention. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States ; Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults. MMWR 2006;55(No. RR-16):

[ 2 ] Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 Feb;45(2):507-39.

Aggregate data presented by the National HIVQUAL Project indicates approximately one-third of clients receive an annual dental screening. [ 3 ] While many primary care providers are not in a position to assure dental care is available, oral exams performed by a dentist remains a critical part of primary care. It is important to establish the baseline frequency of services being rendered and as a result, have been included in the core clinical performance measures. Such data may help document gaps in care.

[ 3 ] http://www.hivguidelines.org/admin/files/qoc/hivqual/proj%20info/HQNatlAggScrs3Yrs.pdf

A dental screening can be performed by any trained health care professional and is used to determine whether dental services are required. An oral exam includes a comprehensive examination of hard and soft tissues in the oral cavity and must be completed by a dentist. The focus of this measure is to determine the percentage of clients who receive an annual oral exam, and therefore, must be completed by a dentist. For purposes of this measure, documentation may be based on patient self report or other documentation.

Very few organizations can provide the full range of services needed by our clients. By default, referrals become a necessary part of the continuum of care. As such, it is important that an organization be able to monitor, track and document the outcome of referrals to ensure the care requirements are being met for each client. Tracking of referrals should be integrated into the system of care and policies and procedures should outline the expectations of the referring agency.